Prêt d’amorçage investissement from Bpifrance
Ventuno Biotech has secured a prêt d’amorçage investissement (PAI) from Bpifrance, in addition to the seed funding round completed last November. The financing represents a key milestone for Ventuno Biotech and strengthens the company’s resources to continue the development of its innovative immunotherapies.
€3M Seed financing
Ventuno Biotech secures €3M Seed financing to advance next generation cancer immunotherapies Lyon, France – November 26th, 2025 – Ventuno Biotech, a biotechnology company developing breakthrough immunotherapies for the treatment of cancer, today announced the completion of a €3 million seed financing round. The operation includes €2 million in equity, led by Octalfa and supported […]
French Tech Emergence Grant
Ventuno Biotech announces today the receipt of the BPI French Tech Emergence Grant (Bourse French Tech Emergence – BFTE). This funding will support the development of an innovative immunotherapy designed to overcome resistance mechanisms in certain difficult-to-treat cancers.
BPI Deeptech label
Ventuno Biotech announces today the receipt of the Deeptech label from BPI France
Ventuno Biotech in BIOTECH FINANCES
Ventuno Biotech is featured in the February 14th issue of 15h Biotech Express by BIOTECH FINANCE. Read online in BIOTECH FINANCES
Launch of Ventuno Biotech
Ventuno Biotech is launched to transform the landscape of cancer immunotherapy